180 LIFE SCIENCES CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.83 USD | -4.19% |
|
-17.57% | -54.89% |
| Mar. 25 | 180 Life Sciences Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 11 | 180 Life Sciences Corp. Announces Board Changes | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor (anti-TNF). SCAs platform is focused on drugs which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). a7nAChR platform is focused on alpha 7 nicotinic acetylcholine receptor (a7nAChR). It is conducting clinical trials only for certain indications under the anti-TNF platform. The Company is undertaking preclinical research and development activities for the SCA platform.
| 1st Jan change | Capi. | |
|---|---|---|
| -54.89% | 1.56M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -0.44% | 21.66B | |
| -18.35% | 20.77B | |
| -7.45% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- KBLM Stock
- News 180 Life Sciences Corp.
- 180 Life Sciences Appoints Quan Vu as Chief Operating Officer
